home / stock / ogen / ogen news

OGEN News and Press, Oragenics Inc. From 08/20/19

Stock Information
Company Name: Oragenics Inc.
Stock Symbol: OGEN
Market: NYSE
Website: oragenics.com
Menu
OGEN OGEN Quote OGEN Short OGEN News OGEN Articles OGEN Message Board
Get OGEN Alerts

News, Short Squeeze, Breakout and More Instantly...
OGEN - Oragenics, Inc. to Present Overview of Lantibiotics Pipeline at the Annual Military Health System Research Symposium

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announces it will be presenting a talk titled “Lantibiotics, a Novel Class of Antibiotics in the Pha...
OGEN - Oragenics, Inc. to Present Data on Its Peptide Synthesis Platform at the American Peptide Symposium

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announces it will be presenting at the American Peptide Symposium on their novel peptide synthesis platform...

OGEN - Recent Peer-Reviewed Publication on Oragenics, Inc.'s Lantibiotic Antimicrobial Compound Identifies Alternative Mechanism of Action

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announces the publication of a collaborative study investigating an additional mechanism of action of the ...

OGEN - Oragenics up 12% on advancement of oral mucositis candidate

Nano cap Oragenics ( OGEN +12.4% ) is up on over 50% higher volume in reaction to its announcement that over 80 subjects have been enrolled in its Phase 2 clinical trial evaluating AG013 for the treatment of oral mucositis (OM) in patients undergoing chemoradiation for head and neck ...
OGEN - Oragenics, Inc. Provides Development Update of AG013 for Oral Mucositis

Phase 2 Clinical Trial Enrollment Progresses While World Health Organization Provides Generic Name of AG013 Compound Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“O...

OGEN - Newly Published Preclinical Data on Oragenics, Inc.'s Lantibiotic Compound Demonstrates Tolerability and Compartmentalization to the GI Tract

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announced the publication of preclinical data of the company’s lantibiotic compound OG253, a predec...

OGEN - Oragenics, Inc. to Present at Spring Investor Summit on April 1, 2019

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), today announced it will present and meet with investors at Spring Investor Summit on April 1, 2019 at 1:00 PM ET as part of Trac...
OGEN - Oragenics, Inc. Enters into Collaboration with Florida International University to Expand Its Pipeline of Lantibiotics

Oragenics, Inc. (NYSE American:OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (“OM”), today announced the initiation of a collaboration with Florida International University (FIU) to create computati...

OGEN - Oragenics Announces Closing of $12.5 Million Underwritten Public Offering

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced the closing of its previously announced underwritten public offering of 16,666,668 shares of common stock, short-term...

OGEN - Oragenics Announces Pricing of $12.5 Million Underwritten Public Offering

Oragenics, Inc. (NYSE American: OGEN), a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, today announced the pricing of its previously announced underwritten public offering of 16,666,668 shares of common stock, short-term...
Previous 10 Next 10